Locally Advanced (includes T3 tumors) , Metastatic Bladder Cancer (includes T4 tumors)

Targeted therapy

Targeted therapy

People with bladder cancer that has spread (metastatic) or cannot be removed by surgery.

This treatment combines two medicines that work in different ways:

• Enfortumab vedotin targets a protein (called Nectin-4) found on most bladder cancer cells and delivers medicine directly to kill those cells.
• Pembrolizumab helps your immune system find and attack cancer cells.

Together, they help stop or slow the growth of bladder cancer.

Given as the first treatment for people with advanced or metastatic bladder cancer.

Both medicines are given by IV (into a vein) at the clinic or hospital.

• Enfortumab vedotin is usually given once a week for 2 weeks, then 1 week off.
• Pembrolizumab is usually given once every 3 or 6 weeks. Your doctor will decide the best schedule for you.

Common side effects may include:

• Tiredness
• Rash, itchiness or dry skin
• Numbness or tingling in hands or feet
• Diarrhea or loss of appetite
• Changes in blood sugar (especially in people with diabetes)

Less common but serious side effects may include:

• Nerve problems
• Lung, liver, or thyroid inflammation
• Severe skin reactions
• Blurry vision

Always tell your doctor right away if you have new or worsening symptoms.